NONPROPRIETARY (USAN/INN) NAMING SERVICES

Drug Safety Institute, provides regulatory nonproprietary nomenclature research, labeling, packaging, and risk management services utilizing proven methodologies developed by the most highly qualified personnel.

Drug Safety Institute can provide strategic guidance that will assist you in navigating the pharmaceutical naming process from initiation through regulatory submission.

Sophia V. Fuerst nee Rybak

Mrs. Fuerst was formerly the Director of the American Medical Association's United States Adopted Names (USAN) Program and served as secretary to the USAN Council, which involved negotiations between the USAN Council, pharmaceutical manufacturers, and foreign nomenclature agencies. She also served as the AMA's senior staff scientist in the area of Drug Nomenclature. Mrs. Fuerst has 20 years of national and international nomenclature and drug safety experience.

  Related Links

  - FDA
  - FDA MedWatch
  - FDA (AERS)
  - USP
  - Health Canada
  - EMEA
  - NCC MERP
 

Related Articles

Brand Name Analysis
Drug Experts
Drug Labeling 1
Drug Labeling 2
Drug Labeling 3
Drug Labeling 4
Drug Name Review
Drug Packaging
Drug Packaging 2
Drug Safety
Drug Safety 2
Effect Analysis
FDA Report
FMEA
FMEA
Generic Drugs
Health Canada Report
Health Canada Report
Look Alike
Medication Safety
Medication Error
Medication Error
Post-marketing Risk Assessment
Risk Minimization
Safe Medication Practices
Stigmatized Diseases

More Articles